At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 20 target
Drug / intervention
Tislelizumab +2 moredrug
Likely dose
Tislelizumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of the Efficacy and Safety of PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in the Second-line Treatment of Recurrent or Metastatic Anaplastic Thyroid Cancer
In Brief
A Phase 2 clinical trial evaluating Tislelizumab, Anlotinib, and 1 other intervention for Thyroid Cancer. Targeting 20 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of PD-1 inhibitor and anlotinib combined with multimodal radiotherapy for the second-line treatment of recurrent or metastatic anaplastic thyroid cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThyroid Cancer
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
2023202420252026
First PostedDec 2022
Enrollment StartDec 2022
Primary CompletionDec 2024
Study CompletionDec 2025
TodayJul 2026
First PostedDec 21, 2022
Enrollment StartDec 30, 2022
Primary CompletionDec 30, 2024
Study CompletionDec 30, 2025
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 3.5 years ago
Interventions
Tislelizumabdrug
200mg IV Q3W
Anlotinibdrug
12mg PO QD
Radiotherapyradiation
Multimodal Radiotherapy